Accelerating Digitalization in Healthcare with the InSilicoTrials Cloud-Based Platform: Four Use Cases

Figure 1. Schematic representation of the InSilicoTrials.com collaborative model. Through a cloud-based platform, InSilicoTrials.com provides Pharma and MedTech companies with computational models developed by internationally recognized universities and research centers. Computational models are integrated into user-friendly simplified workflows, which user can access with the highest level of data security in a pay-per-use way.

Figure 2. QT/TdP Risk Screen and STrhiPS drug-induced cardiotoxicity predictions. (a) QT/TdP Risk Screen clinical risk classification of a dataset of known drugs at therapeutic concentration Cmax. (b) Difference in the action potential duration at 90% of repolarization (APD90) safety marker in absence and presence of drug simulated in a population of 110 hiPSC-CMs by STrhiPS.

Figure 3. SEV Radial Force Test simulation results of the characterization of device radial force. Radial force as a function of the crimping diameter for a model representing a Corevalve 29 mm with crimping diameter equal to 10 mm. The blue and orange lines represent respectively the Radial Resistive Force, exerted during the radial compression, and Chronic Outward Force, exerted during the radial expansion, as a function of the diameter.

Figure 4. MS TreatSim results of the recreation of a natalizumab historical trial. (a) Kaplan–Meier curves of the relapse free patients in the natalizumab group and control group. Shaded areas denote 95% confidence intervals. (b) Bubble plot of total number of B cells (y-axis) vs. total number of CD4 T cells (x-axis) concentrations averaged over the entire trial duration. Markers represent individual virtual patients; markers sizes are scaled by the individual’s relapse rate, so that large markers denote patients with high relapse rates.

Figure 5. Results of the leuprolide cohorts recreation using PCa GnRH Agonists Simulator. Visual predictive checks of the drug plasma concentration (top row) and testosterone plasma concentration (bottom row) of the three schedules (3M leuprolide, 4M leuprolide and 6M leuprolide in the first, second and last column, respectively). Continuous lines represent the median simulated profiles in the time frame where real clinical data are available; dotted lines are the median of the simulated profiles in the time frame where clinical data are not available; shaded areas represent the 95% prediction intervals obtained from 1000 individual simulated profiles. In the bottom row, black dots represent the experimental mean testosterone levels in plasma from previous studies. The red dashed line represents the testosterone concentration castration limit (0.5 ng/mL). 3M leuprolide = 22 mg leuprolide injected once every 3 months; 4M leuprolide = 30 mg leuprolide injected once every 4 months; 6M leuprolide = 45 mg leuprolide injected once every 6 months.